Parkinson’s Disease Stem Cell Treatment in Delhi, India
Parkinson’s disease is a progressive neurological disorder primarily affecting movement. The disorder presents when a number of nerve cells in the brain lose their ability to produce enough dopamine, a necessary neurotransmitter that helps control coordination and muscle control. If dopamine isn’t produced in adequate supply, the brain will send improper signals to the body. Eventually, people will experience tremors and stiffness and will have difficulty making movements. It is common for the symptoms to take many years to appear, and they always worsen with time.
The disease attacks nerve cells in the basal ganglia, or its deepest area of the brain. Aging is a significant risk factor, in addition to exposure to environmental toxins. Usually, Parkinson’s disease is diagnosed in adults over the age of 50, although some people develop it at a much younger age. In the United States alone, there are almost 1 million cases of Parkinson’s, and the incidence is almost equal in men and women.
Affect is a small part of the involvement of genetics. Parkinson’s disease is not contagious, but having a first-degree relative with this condition may increase your risk of developing it.
Currently, stem cell therapy for Parkinson’s disease in India, particularly at advanced centers in Delhi, has been showing some promising results. The goal of this treatment is to restore cells that produce dopamine to improve motor function and overall quality of living.
Symptoms of Parkinson’s Disease
Parkinson’s disease targets the central nervous system and most often begins simply, gradually, and regularly worsening.
The four main indicators of Parkinson’s disease:
- Slow moment (bradykinesia)
- Tremors, typically manifested as shaking of the hands, arms, or legs
- Stiff or rigid muscles
- Difficulty balancing or walking
In early stages, hand tremors may be the most visible sign of Parkinson’s; however, as the disease progresses, people can be unable to stand or walk properly, and the coordination of body movements can become challenged.
Stiffness and overall slowness in actions can greatly hinder the activities of daily life.
Additionally, Parkinson’s may also start to affect facial expressions, speech, and swallowing abilities during the course of the disease. Patients may, for example, develop a fixed or expressionless face, even if they are experiencing emotional changes. It is common for patients to have issues with their memory, focus, and decision-making abilities.
Because balance is affected, falls and broken bones can be common occurrences in patients. Patients may also experience emotional factors such as depression or simply lose interest in activities that they previously engaged in.
Parkinson’s disease is progressive, but many patients go for many years—Parkinson’s progresses at a very slow pace; in fact, many patients can expect to live for many years with proper care and treatment.
In recent years, stem cell treatment for Parkinson’s disease in India has recently become a trend to help improve patients’ motor function and quality of life.
Types of Parkinson’s Disease
Parkinson’s disease (PD) is a chronic neurological disorder that makes it hard to control movement and ultimately interferes with everyday life. Roughly estimated to be present in 1% of people over the age of 65. Most people view PD as one illness; however, it has several forms with different characteristics.
Idiopathic Parkinson’s Disease:
This is the most common type of PD and typically when a person is diagnosed around age 60. The cause of idiopathic PD is unclear and is thought to be a mix of genetic and environmental factors. Symptoms commonly include tremors, stiffness, and slower movements.
Juvenile and Early-Onset Parkinson’s Disease:
Juvenile PD occurs before age 21, whereas early-onset PD occurs between ages 21 and 40. Other than rarity, these two types are like idiopathic PD, but they progress more slowly. The symptoms may feel more severe for the patients due to being in the prime of their life.
Multiple System Atrophy (MSA):
A neurodegenerative disorder affecting both movement and the autonomic nervous system, characterized by alpha-synuclein protein buildup in glial cells, where it frequently impairs speech, causes uncoordinated movement, and leads to sleep problems, typically starting after the age of 50.
Progressive Supranuclear Palsy (PSP):
Also referred to as Steele-Richardson-Olszewski syndrome, PSP is a more rapidly progressing disease than typical PD, usually emerging after age 50 with symptoms of rigidity, bradykinesia, and balance problems resulting from the unique degeneration involving cortex-related areas of the brain that control appropriate sequencing of movement.
Drug-Induced Parkinsonism:
The second most common presentation of Parkinsonism is when specific medications impact dopamine transmission. It typically occurs in older patients (average age of 70), and when clinically noted, stopping the offending drug can improve symptoms.
Corticobasal Syndrome:
A rare variety of Parkinsonism due to tau protein deposits in the brain characterized by rigid limbs (usually one side), tremors, speech difficulties, swallowing problems, and possible dementia.
Vascular Parkinsonism:
This condition results from small strokes in parts of the brain that control movement. It causes tremors, stiffness, mental slowness, and problems with gait, usually more severe in the lower body.
Dementia with Lewy Bodies (DLB):
DLB is particularly problematic in those over 50 and is characterized by loss of cognitive function, memory, insight, and vivid hallucinations and loss of REM sleep. Patients may show mixed motor symptoms of Parkinson’s and dementia.
Causes and Risk Factors of Parkinson’s Disease
The cause of Parkinson’s disease is not straightforward. Researchers now consider that its origin is both complex and multi-faceted, as it likely arises from a combination of genetic and environmental influences as well as processes that are happening in nerve cells of the brain.
That said, genetic factors do play a role in a small percentage of cases. A few specific genetic mutations have been identified and can increase susceptibility to Parkinson’s (the risk is most frequently seen in families in which multiple family members are affected); however, genetic Parkinson’s is still considered comparatively rare.
So-called environmental influences may sometimes contribute too. Prolonged exposure to toxins, pesticides, or heavy metals may contribute to risk too—and there are lifestyle factors too (e.g., history of smoking, alcohol use, age) that have been related to increased risk for Parkinson’s compared to others. The interaction of these environmental exposures along with the genetic predisposition is being explored.
One important biological marker for Parkinson’s disease consists of the presence of Lewy bodies, which are abnormal clumps that develop inside nerve cells of the brain. Within Lewy bodies, a protein called alpha-synuclein is stored in an abnormal way. Alpha-synuclein is normally found throughout the body, but when it appears in the developing Parkinsonian brain, it is seen in an abnormal accumulation pattern, linked to disruption of brain function. Researchers now regard this protein as important not only to Parkinson’s disease but also relevant to related neurodegenerative conditions that impair movement and cognition.
These factors generally point to the presence of multifactorial disease in Parkinson’s, which appears to develop from inheritable processes and clearly.
Diagnosis of Parkinson’s Disease
Your health care provider may order certain tests to determine if you have Parkinson’s disease. Some of the tests include:
Blood tests may be done to check thyroid hormone levels or liver damage.
An imaging test (such as a CT scan or an MRI) may be used to determine if there is a stroke or a brain tumor.
PET scanning may sometimes detect low dopamine levels in the brain, which is indicative of Parkinson’s. However, PET scans are not used to evaluate Parkinson’s because they are expensive, not in many hospitals, and only used experimentally.
Treatment for Parkinson’s Disease
Recent studies show that umbilical cord mesenchymal stem cells have the ability to differentiate into nerve cells, neovascularize (baby formation of blood vessels), and immunomodulate when placed into the damaged area, thus causing improvement in symptoms and prolonging lives. As you can see, steroids and other disease-modifying drugs do not address all symptoms and, in fact, are aimed at specific symptoms only, and again, there is always the concern of adverse side effects with drugs. With MSC treatment, there is no such issue.
FAQs
1. Can stem cell therapy cure Parkinson’s disease?
There is currently no permanent cure for Parkinson’s. Stem cell therapy focuses on restoring dopamine-producing cells, which helps improve motor function, reduce symptoms, and enhance quality of life.
2. Why consider stem cell treatment for Parkinson’s in Delhi?
Delhi hosts advanced medical centers with modern facilities, experienced neurologists, and affordable treatment options. Patients also receive personalized care, making India a leading destination for international medical travelers.
3. Is stem cell therapy safe for Parkinson’s patients?
Most centers in Delhi use mesenchymal stem cells (MSCs), which are considered safe and effective. Unlike drugs that manage only specific symptoms, MSCs target the disease at a cellular level with fewer serious side effects.
4. Who can benefit from stem cell treatment for Parkinson’s?
Patients in the early or mid-stages of Parkinson’s disease, experiencing tremors, stiffness, or movement difficulties, may benefit most. A neurologist’s evaluation is necessary to determine eligibility.